AGE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. AgeX Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.08 Mil. AgeX Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $12.09 Mil. Therefore, AgeX Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.01.
Asset Turnover is linked to ROE % through Du Pont Formula. AgeX Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was 125.29%. It is also linked to ROA % through Du Pont Formula. AgeX Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -114.37%.
The historical data trend for AgeX Therapeutics's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AgeX Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Asset Turnover | Get a 7-Day Free Trial | 0.19 | 0.06 | 0.04 | 0.01 | 0.02 |
AgeX Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Asset Turnover | Get a 7-Day Free Trial | - | - | - | - | 0.01 |
For the Biotechnology subindustry, AgeX Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's Asset Turnover distribution charts can be found below:
* The bar in red indicates where AgeX Therapeutics's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
AgeX Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2023 ) | / | ( (Total Assets (A: Dec. 2022 ) | + | Total Assets (A: Dec. 2023 )) | / count ) |
= | 0.142 | / | ( (3.241 | + | 11.965) | / 2 ) |
= | 0.142 | / | 7.603 | |||
= | 0.02 |
AgeX Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | 0.077 | / | ( (12.21 | + | 11.965) | / 2 ) |
= | 0.077 | / | 12.0875 | |||
= | 0.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
AgeX Therapeutics (AMEX:AGE) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
AgeX Therapeutics's annulized ROE % for the quarter that ended in Dec. 2023 is
ROE %** | (Q: Dec. 2023 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -13.824 | / | -11.0335 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-13.824 / 0.308) | * | (0.308 / 12.0875) | * | (12.0875/ -11.0335) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | -4488.31 % | * | 0.0255 | * | -1.0955 |
= | ROA % | * | Equity Multiplier | ||
= | -114.37 % | * | -1.0955 | ||
= | 125.29 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
AgeX Therapeutics's annulized ROA % for the quarter that ended in Dec. 2023 is
ROA % | (Q: Dec. 2023 ) | ||
= | Net Income | / | Total Assets |
= | -13.824 | / | 12.0875 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (-13.824 / 0.308) | * | (0.308 / 12.0875) |
= | Net Margin % | * | Asset Turnover |
= | -4488.31 % | * | 0.0255 |
= | -114.37 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of AgeX Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Jean-christophe Renondin | director | 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022 |
Juvenescence Us Corp. | director, 10 percent owner | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Joanne M. Hackett | director | C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708 |
Park Andrea Eun Jae | officer: Chief Financial Officer | C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501 |
Michael H May | director | 965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501 |
Michael D West | director, officer: Chief Executive Officer | AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501 |
Michael H. Mulroy | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Russell Skibsted | officer: Chief Financial Officer | 15 TRANQUILITY PLACE, LADERA RANCH CA 92694 |
Judith Segall | officer: Corporate Secretary | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Hal Sternberg | officer: Vice President-Research | 935 PARDEE STREET, BERKELEY CA 94710 |
Annalisa Jenkins | director | C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555 |
John F Mauldin | director | 3204 BEVERLY DRIVE, DALLAS TX 75205 |
Gregory Bailey | director | 4 A CHESHAM STREET, LONDON X0 SW1X8DT |
Juvenescence Ltd | 10 percent owner | 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB |
Nafees Naseer Malik | officer: Chief Operating Officer | C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501 |
From GuruFocus
By PRNewswire • 09-26-2023
By PRNewswire • 09-19-2023
By PRNewswire • 09-06-2023
By Marketwired • 08-30-2023
By PRNewswire • 10-10-2023
By Marketwired • 10-18-2023
By PRNewswire • 08-30-2023
By Marketwired • 09-15-2023
By PRNewswire PRNewswire • 09-10-2019
By PRNewswire • 10-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.